Mechanisms Controlling BubR1 Regulation of Cancer and Aging

BubR1 调节癌症和衰老的控制机制

基本信息

  • 批准号:
    9897456
  • 负责人:
  • 金额:
    $ 12.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-30 至 2021-10-31
  • 项目状态:
    已结题

项目摘要

Abstract: The goal of this proposal is to elucidate the molecular mechanisms governing BubR1 protein abundance and function, and its role in the regulation of tumorigenesis and aging. Aging is the single greatest risk factor for cancer development, yet the mechanistic basis driving this interrelationship remains largely undefined. BubR1, a serine/threonine protein kinase, is involved in the spindle assembly checkpoint (SAC) to ensure faithful chromosome segregation during mitosis, and therefore is intimately linked to genomic integrity and cancer. Interestingly, recent studies have implicated BubR1 in the aging process where BubR1 abundance has been shown to decline in a variety of tissues as mammals age. Mice engineered to express low levels of BubR1 from birth die within a year, exhibiting increased senescence, premature aging phenotypes and an increased susceptibility to cancer, whereas mice overexpressing BubR1 have an extended lifespan with reduction in age- related diseases and cancer development. Senescence is believed to be largely tumor-suppressive and prevent cancer in young individuals. However, in aged individuals senescent cells can contribute to age-related cancer development. Therefore, BubR1 may play a pivotal role in the interrelationship between aging and cancer given that BubR1 suppresses both senescence and tumorigenesis. Previously, we identified an acetylation-dependent mechanism regulating BubR1 protein stability, where SIRT2 prevents degradation of BubR1 through deacetylation, leading to lifespan extension of a BubR1 premature aging mouse model. Furthermore, BubR1 protein levels in aged animals can be restored to youthful levels by stimulating SIRT2 activity through induction of NAD+ levels. These results suggest that the age-related decline in BubR1 levels can be reversed, potentially alleviating age-related diseases including cancer. Therefore, we hypothesize that BubR1 is a key tumor suppressor, and its loss with age increases cancer susceptibility. In this proposal, we plan to: 1) elucidate the physiological role of BubR1 post translational modifications during aging and calorie restriction and their impact on mitotic progression and tumorigenesis; and 2) determine the mechanisms regulating BubR1 protein abundance and function during aging. These studies will elucidate how regulation of BubR1 by post-translational modifications controls mitotic progression and tumorigenesis during aging as well as to identify mechanisms through which BubR1 declines with age and controls the aging processes. Given that aging poses the largest single risk factor for developing cancer, elucidating the molecular details governing the physiological role of BubR1 in cancer and aging will provide mechanistic understanding of the interrelationship between aging and cancer development, as well as identify possible therapeutic strategies to treat age-related diseases.
摘要: 该提案的目标是阐明控制BubR 1蛋白丰度的分子机制, 功能及其在肿瘤发生和衰老调节中的作用。衰老是最大的风险因素 癌症的发展,但驱动这种相互关系的机制基础仍然在很大程度上不明确。BubR1, 丝氨酸/苏氨酸蛋白激酶,参与纺锤体组装检查点(SAC),以确保忠实的 在有丝分裂期间染色体分离,因此与基因组完整性和癌症密切相关。 有趣的是,最近的研究表明,BubR 1在老化过程中,BubR 1的丰度一直是 随着哺乳动物年龄的增长,经工程改造以表达低水平BubR 1的小鼠 从出生一年内死亡,表现出增加的衰老,过早老化表型和增加的 对癌症的易感性,而过表达BubR 1的小鼠随着年龄的减少寿命延长, 相关疾病和癌症的发展。衰老被认为在很大程度上是肿瘤抑制性的, 预防年轻人的癌症然而,在老年人中,衰老细胞可以促进与年龄相关的衰老。 癌症发展因此,BubR 1可能在衰老和衰老之间的相互关系中发挥关键作用。 考虑到BubR 1抑制衰老和肿瘤发生,此前,我们发现了一个 乙酰化依赖性机制调节BubR 1蛋白的稳定性,其中SIRT 2阻止BubR 1蛋白的降解。 BubR 1通过去乙酰化,导致BubR 1早衰小鼠模型的寿命延长。 此外,通过刺激SIRT 2,老年动物中的BubR 1蛋白水平可以恢复到年轻水平。 通过诱导NAD+水平的活性。这些结果表明,年龄相关的BubR 1水平下降, 可以逆转,潜在地减轻与年龄有关的疾病,包括癌症。因此,我们假设 BubR 1是一种关键的肿瘤抑制因子,随着年龄的增长,它的丢失会增加癌症的易感性。在本提案中,我们 计划:1)阐明BubR 1翻译后修饰在衰老和卡路里代谢中的生理作用。 限制及其对有丝分裂进程和肿瘤发生的影响;和2)确定机制 在衰老过程中调节BubR 1蛋白的丰度和功能。这些研究将阐明如何调节 BubR 1通过翻译后修饰控制衰老过程中的有丝分裂进程和肿瘤发生 以确定BubR 1随年龄增长而下降并控制衰老过程的机制。给定 衰老是癌症发生的最大单一风险因素,阐明了控制癌症的分子细节, BubR 1在癌症和衰老中的生理作用将提供对癌症的机制性理解。 衰老和癌症发展之间的相互关系,以及确定可能的治疗策略, 治疗与年龄有关的疾病。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
  • DOI:
    10.1007/s11033-021-06665-7
  • 发表时间:
    2021-09
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Ma Y;North BJ;Shu J
  • 通讯作者:
    Shu J
Physiological relevance of post-translational regulation of the spindle assembly checkpoint protein BubR1.
纺锤体组装检查点蛋白 BubR1 翻译后调节的生理相关性。
  • DOI:
    10.1186/s13578-021-00589-2
  • 发表时间:
    2021-04-23
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    Bloom CR;North BJ
  • 通讯作者:
    North BJ
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Cullin 3spop泛素E3连接酶促进HDAC6的多泛素化和降解。
  • DOI:
    10.18632/oncotarget.18141
  • 发表时间:
    2017-07-18
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tan Y;Ci Y;Dai X;Wu F;Guo J;Liu D;North BJ;Huo J;Zhang J
  • 通讯作者:
    Zhang J
Unraveling the Molecular Nexus between GPCRs, ERS, and EMT.
  • DOI:
    10.1155/2021/6655417
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Kumari N;Reabroi S;North BJ
  • 通讯作者:
    North BJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian J. North其他文献

E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities
癌症干细胞中的 E3 泛素连接酶:癌症标志和新治疗机会的关键调节因子
  • DOI:
    10.1007/s13402-023-00777-x
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    6.6
  • 作者:
    Qiang Zou;Meng Liu;Kewei Liu;Yi Zhang;Brian J. North;Bin Wang
  • 通讯作者:
    Bin Wang
Measurement of mammalian histone deacetylase activity.
哺乳动物组蛋白脱乙酰酶活性的测量。
  • DOI:
    10.1016/s0076-6879(03)77010-4
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    E. Verdin;F. Dequiedt;W. Fischle;Roy A. Frye;Brett L Marshall;Brian J. North
  • 通讯作者:
    Brian J. North
Conclusions and Research Perspectives
结论和研究观点
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pengda Liu;Brian J. North;H. Inuzuka;Wenyi Wei
  • 通讯作者:
    Wenyi Wei
The Class III Protein Deacetylases
III 类蛋白质脱乙酰酶
  • DOI:
    10.1385/1-59745-024-3:237
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    B. Schwer;Brian J. North;N. Ahuja;Brett L Marshall;E. Verdin
  • 通讯作者:
    E. Verdin

Brian J. North的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian J. North', 18)}}的其他基金

Regulatory Mechanisms Governing BubR1 Protein Stability During Stress and Aging
压力和衰老过程中 BubR1 蛋白稳定性的调控机制
  • 批准号:
    10419290
  • 财政年份:
    2022
  • 资助金额:
    $ 12.39万
  • 项目类别:
Regulatory Mechanisms Governing BubR1 Protein Stability During Stress and Aging
压力和衰老过程中 BubR1 蛋白稳定性的调控机制
  • 批准号:
    10624953
  • 财政年份:
    2022
  • 资助金额:
    $ 12.39万
  • 项目类别:
Characterizing upstream regulators of glucosylceramide metabolism for Parkinson's disease and Lewy Body Dementia
帕金森病和路易体痴呆的葡萄糖神经酰胺代谢上游调节因子的特征
  • 批准号:
    10323690
  • 财政年份:
    2021
  • 资助金额:
    $ 12.39万
  • 项目类别:
Mechanisms Controlling BubR1 Regulation of Cancer and Aging
BubR1 调节癌症和衰老的控制机制
  • 批准号:
    9353713
  • 财政年份:
    2016
  • 资助金额:
    $ 12.39万
  • 项目类别:
Mechanisms Controlling BubR1 Regulation of Cancer and Aging
BubR1 调节癌症和衰老的控制机制
  • 批准号:
    9180131
  • 财政年份:
    2016
  • 资助金额:
    $ 12.39万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.39万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了